Table 1

Baseline characteristics of the intracerebral haemorrhage cohort (all patients with intracerebral haemorrhage, comparing patients taking oral anticoagulants prior to ICH onset with those patients not taking anticoagulants) and atrial fibrillation cohort (all patients with ischaemic stroke, atrial fibrillation and oral anticoagulant therapy comparing patients with none–low small vessel disease burden (small vessel disease absent) to those with medium–high small vessel disease burden (small vessel disease present))

		Intracerebral haemorrhage cohort			Atrial fibrillation cohort
		On prior anticoagulation therapy (n=421)	Without prior anticoagulation therapy (n=609)	P value	Small vessel disease burden present (n=779)	Small vessel disease burden absent (n=668)	P value
Age		79 (72–84)	72 (62–80)	<0.001	80 (73–85)	73 (66–80)	<0.001
Female sex		175 (41.6%)	264 (43.4%)	0.548	336 (43.1%)	275 (41.2%)	0.451
NIHSS on admission		6 (3–13)	8 (4–13)	0.115	4 (2–9)	5 (2–11)	0.169
GCS on admission		15 (14–15)	15 (14–15)	0.126	n/a	n/a	n/a
Haemorrhage volume in ml	All locations	7.2 (2.4–20.6)	6.9 (2.1–16.0)	0.198	n/a	n/a	n/a
	Deep location	5.5 (1.6–12.2)	4.4 (1.6–10.4)	0.237
	Lobar location	17.5 (5.0–35.3)	15.0 (6.7–31.7)	0.760
INR on admission		2.3 (1.8–3.0)	1.0 (1.0–1.1)	<0.001	n/a	n/a	n/a
*Medical history*
History of intracerebral haemorrhage		11 (2.6%)	32 (5.3%)	0.028	5 (0.7%)	3 (0.5%)	0.624
History of ischaemic stroke		75 (17.8%)	58 (9.5%)	<0.001	99 (12.9%)	41 (6.3%)	<0.001
Atrial fibrillation		326 (79.1%)	33 (6.1%)	<0.001	779 (100%)	668 (100%)	n/a
Hypertension		310 (73.6%)	372 (61.1%)	<0.001	541 (71.1%)	365 (55.0%)	<0.001
Myocardial infarction		51 (12.1%)	35 (5.8%)	<0.001	87 (11.3%)	44 (6.6%)	0.002
Hypercholesterolaemia		212 (50.4%)	237 (38.9%)	<0.001	344 (44.9%)	293 (44.4%)	0.853
Current smoker		24 (5.7%)	84 (13.8%)	<0.001	79 (10.5%)	80 (12.2%)	0.587
Diabetes mellitus		99 (23.5%)	90 (14.8%)	<0.001	135 (17.3%)	107 (16.1%)	0.521
Antiplatelet agent therapy		51 (12.1%)	208 (34.2%)	<0.001	33 (5.2%)	43 (5.6%)	0.568